New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
09:31 EDTLGNDLigand, Avion Pharmaceuticals sign Captisol license agreement
Avion Pharmaceuticals announces the signing of a commercial license agreement with Ligand Pharmaceuticals for the development and commercialization of four Captisol-enabled programs. Under the terms of the agreement, Ligand is entitled to receive an up-front payment, and is eligible to receive revenue from Captisol material sales, potential milestone payments, and royalties on future net sales of the products containing Captisol.
News For LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
11:31 EDTLGNDLigand price target raised to $127 from $116 at Roth Capital
Roth Capital raised its price target for Ligand Pharmaceuticals to $127 citing pipeline expansion following the company's Q1 results. Roth recommends "steady accumulation" of the stock and keeps a Buy rating on the name.
08:35 EDTLGNDLigand sees Q2 adjusted EPS 37c-40c, consensus 35c
Subscribe for More Information
08:34 EDTLGNDLigand affirms FY15 adjusted EPS view $2.14-$2.18, consensus $2.13
Subscribe for More Information
08:34 EDTLGNDLigand reports Q1 adjusted EPS 33c, consensus 27c
Reports Q1 revenue $14.6M, consensus $13.53M.
08:16 EDTLGNDLigand acquires rights to over 15 fully-funded development programs from Selexis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use